| 11/10/2009 | CV | Life Technologies 2% convertible senior notes convertible to Dec. 31
|
| 9/2/2009 | SS | Market Commentary: Danaher buys out joint venture partners; MDS plans more sales; Life Technologies wants deals
|
| 11/21/2008 | SS | Invitrogen, Applied Biosystems combine to form Life Technologies
|
| 11/11/2008 | SS | Merger of Invitrogen, Applied Biosystems could close Nov. 21
|
| 11/11/2008 | SS | Market Commentary: Exelon takes NRG bid to shareholders; Invitrogen, Applied Biosystems merger set to close Nov. 21
|
| 11/4/2008 | SS | Invitrogen, Applied Biosystems to combine as Life Technologies
|
| 10/28/2008 | SS | Merger of Applied Biosystems, Invitrogen one step closer to completion
|
| 10/15/2008 | SS | Invitrogen, Applied Biosystems amend merger agreement, move meetings to Oct. 28
|
| 10/6/2008 | SS | Proxy advisory firms support merger of Invitrogen, Applied Biosystems
|
| 9/19/2008 | BK | Market Commentary: Invitrogen tweaks tranche sizes, breaks; LCDX, cash strengthen; Fresenius, Brocade oversubscribed
|
| 9/19/2008 | BK | Invitrogen upsizes term loan B to $1 billion, downsizes term loan A to $1.4 billion
|
| 9/17/2008 | BK | Market Commentary: Masonite firm on forbearance; Movie Gallery plummets with market; Invitrogen oversubscribed
|
| 9/8/2008 | CVIG | Fitch: Invitrogen supported
|
| 9/5/2008 | BK | Market Commentary: Invitrogen filling up fast; Fresenius Kabi sets Libor floor; LCDX heads higher
|
| 9/3/2008 | BK | Market Commentary: Dollar General up on numbers; Revlon rises with debt paydown plans; Invitrogen, 1-800 Contacts float talk
|
| 9/3/2008 | BK | Invitrogen talks $900 million term B at Libor plus 300 bps to 325 bps, OID 98
|
| 8/29/2008 | BK | Market Commentary: Primary activity to pick up with Brocade, Landry's, 1-800 Contacts and Invitrogen; all set for Sept. 1 week
|
| 8/26/2008 | BK | Invitrogen sets Sept. 5 bank meeting for $2.65 billion credit facility
|
| 8/26/2008 | BK | Market Commentary: Invitrogen sets Sept. 5 bank meeting for $2.65 billion loan; LCDX 5 bps better as traders pass quiet session
|
| 8/25/2008 | SS | Invitrogen shareholders to decide merger with Applied Biosystems on Oct. 16
|
| 8/20/2008 | SS | SAC Capital sells more shares of Invitrogen, keeps 4.1% ownership interest
|
| 8/12/2008 | SS | SAC Capital sells 1.4 million shares of Invitrogen
|
| 8/4/2008 | CVIG | Fitch gives Invitrogen, convertibles BBB-
|
| 7/29/2008 | SS | Invitrogen, Applied Biosystems clear waiting period hurdle
|
| 7/28/2008 | SS | SAC Capital continues to invest in Invitrogen ahead of merger
|
| 7/24/2008 | SS | Invitrogen, Applied Biosystems merger expected in late October-early November
|
| 7/23/2008 | BK | Invitrogen $2.65 billion credit facility expected as September business
|
| 7/23/2008 | BK | Market Commentary: Wrigley nets orders; TriZetto tweaks tranching again; Invitrogen floats pro rata talk; Airlines soar
|
| 7/23/2008 | CVIG | S&P rates Invitrogen BBB-
|
| 7/1/2008 | SS | SAC Capital owns 5.2% of Invitrogen ahead of company's merger with Applied Biosystems
|
| 6/16/2008 | BK | Invitrogen details $2.65 billion credit facility for purchase of Applied Biosystems
|
| 6/12/2008 | BKHY | Invitrogen plans roughly $2 billion of new debt for purchase of Applied Biosystems
|
| 6/12/2008 | CV | Market Commentary: KeyCorp deal eyed ahead of pricing; Lehman active; Coors slips on rival's buyout news; Invitrogen in line
|
| 6/12/2008 | SS | Invitrogen, Applera's Applied Biosystems Group announce $6.7 billion merger agreement
|
| 6/12/2008 | SS | Market Commentary: Analyst anticipates higher bid in Electronic Arts hostile takeover of Take-Two Interactive
|
| 2/20/2008 | CV | Market Commentary: Convertibles thinly traded amid weaker tone; Suntech, Level 3 lower; Encysive surges
|
| 11/8/2006 | BT | Market Commentary: Catalyst higher on debut; Hollis-Eden off 19% on PIPE; stem cell names better; Trimeris rises 23%
|
| 10/30/2006 | CV | Market Commentary: Level 3 gains on takeout rumors; Medis quiet amid borrow concerns; Invitrogen, Red Hat gain slightly
|
| 10/27/2006 | BT | Market Commentary: Genzyme slides on deal buzz; Cadence, Achillion up; Aspreva falls; Vertex gains 18%; Critical off on PIPE
|
| 10/27/2006 | CV | Market Commentary: Wesco gains, Kemet quiet on debut; FiberTower keeps rising; Red Hat higher on buyback; Invitrogen slips
|
| 10/26/2006 | BT | Invitrogen reports third-quarter net loss of $130 million
|
| 9/19/2006 | BT | Invitrogen performing strategic portfolio review
|
| 9/12/2006 | BT | Invitrogen gets contract extension for biothreat detection
|
| 9/7/2006 | BT | Invitrogen buys TEF Labs' calcium ion indicator product lines
|
| 9/1/2006 | BT | Invitrogen to acquire Sentigen for $25.9 million
|
| 8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
| 8/4/2006 | BT | Market Commentary: Invitrogen, CV Therapeutics plunge; Osiris debuts higher, ends steady; Adolor gets eyed
|
| 8/4/2006 | CV | Market Commentary: Scottish Re stays high; Reckson rides counter-bid rumors; Invitrogen shrugs off miss; PDL gains in line
|
| 8/3/2006 | BT | Invitrogen authorizes $500 million stock repurchase program
|
| 7/26/2006 | BT | Jury rules that Stratagene must pay $7.8 million for violating Invitrogen's E. coli patent
|
| 7/21/2006 | BT | Invitrogen to use Genetix technology to screen cell clones
|
| 7/11/2006 | BT | Invitrogen, Human Proteome Organization enter protein research partnership
|
| 7/10/2006 | BT | Invitrogen is first licensing partner for Crucell, DSM Biologics PER.C6 vendor network
|
| 6/29/2006 | BT | Invitrogen licenses stem-cell intellectual property from Geron
|
| 6/29/2006 | BT | Market Commentary: Invitrogen, Geron rise on pact; other stem cell names higher; Keryx up 8%; Nabi up over 2%
|
| 6/27/2006 | BT | Invitrogen, Cellartis collaborate on technology to track stem cell lines
|
| 6/21/2006 | BT | Invitrogen obtains patents to sell Affymetrix's microarrays
|
| 6/21/2006 | BT | Market Commentary: Cell Therapeutics gains on equity financing; Arena higher on data; MedImmune airs $1 billion bond deal
|
| 6/19/2006 | BT | Bear Stearns puts Invitrogen at outperform
|
| 6/13/2006 | BT | Invitrogen, Solexa to supply reagents for sequencing technology
|
| 5/17/2006 | BT | Invitrogen still aiming for $500 million of acquisitions in 2006, looking to increase in-house innovation
|
| 5/16/2006 | BT | Invitrogen, Locus enter broad kinase screening agreement
|
| 4/27/2006 | BT | Invitrogen first-quarter revenue rises to $309 million, net income down
|
| 4/25/2006 | BT | Market Commentary: Serologicals, Millipore both up; other services names dip; DOV, Discovery dive; Neurocrine off
|
| 4/17/2006 | BT | Invitrogen first-quarter revenues increase by 12%
|
| 4/17/2006 | BT | Market Commentary: Invitrogen falls on lower sales forecast; Alkermes rises, dips; Targacept, Vanda gain; Dyax off
|
| 4/11/2006 | BT | Invitrogen, Signalomics to develop multi-color nanotechnology to identify 'faulty' cells
|
| 3/6/2006 | BT | Invitrogen, NIH Chemical Genomics Center form chemical genetics collaboration
|
| 1/9/2006 | BT | Market Commentary: Human Genome, Amgen higher on license pact; Alnylam soars on 2006 view; NPS, Oscient up big
|
| 12/15/2005 | BT | Xcyte sells T cell expansion technology 'Xcellerate Process' to Invitrogen for $5 million
|
| 12/5/2005 | BTCV | Invitrogen buys back $100 million 2.25% convertibles
|
| 12/1/2005 | BT | Invitrogen wins reverse transcriptase patent lawsuit against Clontech
|
| 12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|
| 12/1/2005 | CV | Market Commentary: Platinum debut has shine; Calpine trades mixed; XL Capital, Ceradyne launch new deals
|
| 11/9/2005 | BT | Invitrogen launches Stealth RNAi human kinase collection for use in medical screening
|
| 10/31/2005 | BT | Invitrogen to collaborate with China's National Center for Drug Screening
|
| 10/31/2005 | BT | Market Commentary: NeoPharma skyrockets on new CEO; Charles River Labs higher; Nabi, Indevus, Invitrogen up
|
| 10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
| 10/28/2005 | CV | Market Commentary: Invitrogen drops, but gains on hedge; Amkor steadies after fall; Nektar weaker
|
| 10/25/2005 | CV | Market Commentary: Sovereign slides, Schlumberger, Sepracor lift; Essex reoffered at 98; Flextronics drops after close
|
| 10/6/2005 | BT | Invitrogen acquires Quantum Dot, BioPixels
|
| 10/6/2005 | BT | Market Commentary: Endo, Panacos mixed after deals; Invitrogen off; Oscient plunges; Human Genome continues spiral
|
| 9/14/2005 | BT | Market Commentary: Progenics off on spot sale; profits taken on Celgene rise; Cubist off; Access dives on bankruptcy fears
|
| 9/12/2005 | CV | Market Commentary: Northwest drops as other airline convertibles trade mixed; software names see better bids
|
| 9/9/2005 | BT | Market Commentary: Genomic talk surfaces; Voyager files IPO; Elan joins Biogen fall on restructuring; Sepracor lifted
|
| 7/19/2005 | CV | Market Commentary: Convertibles market sees strength in airlines, energy, as biotechs weaken; Lucent falls, but Lowe's gains
|
| 7/1/2005 | BT | Market Commentary: Altana crushed by Pfizer news; Cubist, Corixa rise in thin market, Millennium off; Cephalon higher
|
| 6/24/2005 | CV | Market Commentary: Convertibles mostly extend losses a second day; biotechs waver, but some energy issues see more gains
|
| 6/23/2005 | BT | Market Commentary: Forest Labs up sharply; King sees buying; Avalon sets IPO range; Salix dives; Xoma, ViaCell bounce
|
| 6/23/2005 | CV | Market Commentary: Convertibles market trades mostly lower, but some energy issues climb with oil prices
|
| 6/21/2005 | CV | Market Commentary: Convertible players eye REIT new issues; Calpine, airline issues lift in pockets of trading
|
| 6/21/2005 | BT | Market Commentary: Critical Therapeutics zooms after financing round; Mylan launches bank facility; Eyetech seen higher
|
| 6/21/2005 | CV | Market Commentary: Convertible players eye REIT new issues; Calpine, airline issues lift in pockets of trading
|
| 6/17/2005 | BT | Market Commentary: Mylan Labs bond deal surfaces; Vertex up, Merck lags; Genentech rises; stem cell names watched
|
| 6/17/2005 | CV | Market Commentary: Convertibles quiet after week's new issues flurry; airlines drift lower; Ford slips as GM edges higher
|
| 6/16/2005 | BTCV | Invitrogen greenshoe exercised, bringing convertible offering to $350 million
|
| 6/16/2005 | CV | Market Commentary: Large MetLife issue takes center stage; Transocean rises with higher oil prices; GM sags
|
| 6/15/2005 | BT | Market Commentary: Mylan leveling off; ev3 seen in trouble, Micrus prices below range; Invitrogen up; ID Biomed eyed
|
| 6/15/2005 | CV | Market Commentary: Convertibles catch wave of optimism as new Invitrogen deal gains favor; Saks sinks after default notice
|
| 6/15/2005 | BTCV | New Issue: Invitrogen sells upsized $325 million convertibles to yield 3.25%, up 27.5%
|
| 6/14/2005 | CV | Market Commentary: Convertibles see more selling ahead of June redemptions; GM, Ford higher, but Calpine, Northwest sink
|
| 6/14/2005 | BT | Market Commentary: Mylan tops biotech activity with big stock buyback; King issues eyed; Invitrogen convertible on tap
|
| 6/13/2005 | CV | Market Commentary: Invitrogen launches $300 million convertible; Connetics, Cephalon stir market; Northwest hits turbulence
|
| 6/13/2005 | BTCV | Invitrogen launches $300 million convertibles talked at 2.75%-3.25%, up 27.5%-32.5%
|
| 5/6/2005 | CV | Invitrogen buys back $125 million 21/4% convertibles
|
| 4/28/2005 | CV | Market Commentary: BearingPoint believers step up; Calpine sell-off gathering steam; Deutsche Telekom convertibles ease
|
| 12/9/2004 | CV | Invitrogen completes exchange for 1.5%, 2% convertibles
|
| 11/9/2004 | CV | Invitrogen starts exchange for 1.5%, 2% convertibles in response to new accounting rules
|
| 7/21/2004 | CV | Market Commentary: Ocwen getting large outright orders; Lucent, telecom zeal fades; Delta skids off highs
|
| 4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
| 2/13/2004 | CV | New Issue: Invitrogen $450 million convertible yield 1.5%, up 32.5%
|
| 2/13/2004 | CV | Market Commentary: Adelphia bonds Earthbound, lose 6 points; Sirius, new paper active but slip to below par levels
|
| 2/12/2004 | CV | Invitrogen $450 million quick-sale convertible talked at 1.25-1.75% yield, 30-35% premium
|
| 2/12/2004 | CV | Market Commentary: Buyers propel new AMR convert; Bristol-Myers up on Erbitux news; Incyte trades at par in gray market
|
| 12/24/2003 | CV | Market Commentary: CKE, Triarc convertibles feel the bite from mad cow scare; Invitrogen shoots up on merger
|
| 11/24/2003 | CV | Market Commentary: Market hunts for Thanksgiving deal, Ciber answers the call with small issue; trading flow low
|
| 8/15/2003 | CV | Invitrogen says greenshoe exercised, raising convertibles to $350 million
|
| 7/30/2003 | CV | Market Commentary: ExpressJet in holding pattern, waiting on Continental signal; three other new deals emerge
|
| 7/29/2003 | CV | New Issue: Invitrogen upsized $325 million convertible yields 2.0%, up 32.5%
|
| 7/29/2003 | CV | Market Commentary: ExpressJet soars in gray market, as do most of new issues in play; Nextel Partners, Dynegy emerge
|
| 7/28/2003 | CV | Invitrogen $300 million quick-sale convertible talked at 1.75-2.25%, up 30-35%
|
| 7/28/2003 | CV | Market Commentary: Dynegy seen launching smaller convert early Tuesday; seven other deals launched Monday
|
| 4/4/2003 | CV | Market Commentary: Yahoo! overnighter meets few cheers; AES plan lifts power group; warning crushes Affymetrix
|
| 12/11/2002 | CV | Market Commentary: Slow day despite new deals; Baxter gets upsized but new Navistar sinks out of the gate
|
| 9/11/2002 | CV | Bear Stearns recommends Invitrogen 5.5% convertibles on heavy hedge
|
| 8/7/2002 | CV | Market Commentary: Convertibles tick up along with stocks, trading spotty still but volumes gain
|
| 7/3/2002 | CV | Market Commentary: Slow, choppy pre-holiday session ends higher
|
| 4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
| 4/10/2002 | CV | Market Commentary: Duane Reade brings new deal in new structure; Biotechs, drugs higher on short covering
|
| 3/21/2002 | CV | Convertibles gain as buyers emerge, PDLI clips slide
|
| 2/28/2002 | CV | Market Commentary: Convertibles choppy, lower but GM deal upped to $3.25 billion
|
| 1/16/2002 | CV | Bear Stearns recommends new Invitrogen convertible on cheapening
|
| 12/7/2001 | CV | Market Commentary: Convertible market slides as stock enthusiasm withers, no new deals
|
| 12/6/2001 | CV | New Issue: Invitrogen upsized $500 million convertibles at 2.25% yield, up 32.5%
|
| 12/6/2001 | CV | Market Commentary: Convertible market slips on thwarted rally in stocks; new issues mixed
|
| 12/5/2001 | CV | Market Commentary: Convertible market roars higher as stocks rally, new deals surge
|
